Clinical Pharmacology of Inflammatory Bowel Disease Therapies

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2000 Nov 18

PMID 11079044

Citations 7

Authors

W J Sandborn

W A Faubion

Affiliations

Soon will be listed here.

Abstract

Knowledge about the clinical pharmacology of medical therapy of inflammatory bowel disease has incrementally advanced. Small studies with mesalamine have suggested that intestinal mucosal concentrations of mesalamine may predict clinical response to mesalamine therapy. Increased expression of glucocorticoid receptor beta and increased expression of the multidrug resistance drug pump P-glycoprotein 170 have been proposed as markers of drug resistance to glucocorticoids. A baseline determination of thiopurine methyltransferase phenotype or genotype may predict early leukopenia in patients treated with azathioprine or 6- mercaptopurine. Serial measurement of erythrocyte 6-thioguanine nucleotides may be useful in tailoring the dose of these medications. A loading dose of intravenous azathioprine does not accelerate the time to response in patients with steroid-treated Crohn's disease; however, standard azathioprine may work more quickly than previously reported. Methotrexate, 15 to 25 mg/wk, is effective for the treatment of Crohn's disease (active or in remission), and there is no significant difference in the erythrocyte concentrations of methotrexate polyglutamate in patients with inflammatory bowel disease receiving 15 mg, compared with 25 mg, subcutaneously on a weekly basis.

Citing Articles

Chrysin ameliorates dextran sulfate-induced ulcerative colitis in mice by modulating inflammation and gut microbiota.

Yao X, Chen Y, Li Y, Mo J, Liu X, Wang P Int J Colorectal Dis. 2025; 40(1):57.

PMID: 40035853 PMC: 11880046. DOI: 10.1007/s00384-025-04843-8.

Overview of Natural Supplements for the Management of Diabetes and Obesity.

Singh S, Shukla A, Sharma S Curr Diabetes Rev. 2023; 20(7):e061123223235.

PMID: 37933216 DOI: 10.2174/0115733998262859231020071715.

root extracts: chemical profile and management of type II diabetes mellitus.

Eltamany E, Nafie M, Khodeer D, El-Tanahy A, Abdel-Kader M, Badr J RSC Adv. 2022; 10(41):24159-24168.

PMID: 35516188 PMC: 9055131. DOI: 10.1039/d0ra03442h.

Molecular Mechanisms of the Anti-Obesity and Anti-Diabetic Properties of Flavonoids.

Hossain M, Abdal Dayem A, Han J, Yin Y, Kim K, Saha S Int J Mol Sci. 2016; 17(4):569.

PMID: 27092490 PMC: 4849025. DOI: 10.3390/ijms17040569.

Antidiabetic properties of dietary flavonoids: a cellular mechanism review.

Vinayagam R, Xu B Nutr Metab (Lond). 2015; 12:60.

PMID: 26705405 PMC: 4690284. DOI: 10.1186/s12986-015-0057-7.

References

Chan G, Erdmann G, Gruber S, Matas A, Canafax D . Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990; 30(4):358-63. DOI: 10.1002/j.1552-4604.1990.tb03606.x. View

Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Iven H . Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62(1):60-73. DOI: 10.1016/S0009-9236(97)90152-1. View

Anstey A, Lennard L, Mayou S, Kirby J . Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med. 1992; 85(12):752-6. PMC: 1293765. DOI: 10.1177/014107689208501213. View

Frieri G, Pimpo M, Andreoli A, Annese V, Comberlato M, Corrao G . Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. Aliment Pharmacol Ther. 1999; 13(5):577-82. DOI: 10.1046/j.1365-2036.1999.00501.x. View

Camma C, Giunta M, Rosselli M, Cottone M . Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997; 113(5):1465-73. DOI: 10.1053/gast.1997.v113.pm9352848. View

Feagan B, Fedorak R, Irvine E, Wild G, Sutherland L, Steinhart A . A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342(22):1627-32. DOI: 10.1056/NEJM200006013422202. View

Egan L, Sandborn W, Mays D, Tremaine W, Lipsky J . Dialysis of the rectum for sampling drug concentrations in the luminal extracellular fluid of the gut: technique and precision. Aliment Pharmacol Ther. 1998; 12(7):679-84. DOI: 10.1046/j.1365-2036.1998.00352.x. View

DAlbasio G, Pacini F, CAMARRI E, Messori A, Trallori G, Bonanomi A . Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997; 92(7):1143-7. View

Weinshilboum R, Sladek S . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32(5):651-62. PMC: 1686086. View

10.

Moshkowitz M, Oren R, Tishler M, Konikoff F, Graff E, Brill S . The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1997; 11(3):569-73. DOI: 10.1046/j.1365-2036.1997.00175.x. View

11.

Frieri G, Pimpo M, Palumbo G, Onori L, Viscido A, Latella G . Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther. 1999; 13(11):1413-7. DOI: 10.1046/j.1365-2036.1999.00642.x. View

12.

Lennard L, VAN LOON J, Weinshilboum R . Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989; 46(2):149-54. DOI: 10.1038/clpt.1989.119. View

13.

Webster , Cidlowski . Mechanisms of Glucocorticoid-receptor-mediated Repression of Gene Expression. Trends Endocrinol Metab. 1999; 10(10):396-402. DOI: 10.1016/s1043-2760(99)00186-1. View

14.

Lennard L, Rees C, Lilleyman J, Maddocks J . Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983; 16(4):359-63. PMC: 1428034. DOI: 10.1111/j.1365-2125.1983.tb02178.x. View

15.

Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T . Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology. 2000; 118(5):859-66. DOI: 10.1016/s0016-5085(00)70172-7. View

16.

Egan L, Sandborn W, Tremaine W, Leighton J, Mays D, Pike M . A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999; 13(12):1597-604. DOI: 10.1046/j.1365-2036.1999.00667.x. View

17.

Colombel J, Ferrari N, Debuysere H, Marteau P, Gendre J, Bonaz B . Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118(6):1025-30. DOI: 10.1016/s0016-5085(00)70354-4. View

18.

Egan L, Sandborn W, Mays D, Tremaine W, Lipsky J . Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999; 5(3):167-73. DOI: 10.1097/00054725-199908000-00004. View

19.

Sandborn W, Tremaine W, Wolf D, Targan S, Sninsky C, Sutherland L . Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999; 117(3):527-35. DOI: 10.1016/s0016-5085(99)70445-2. View

20.

Bourgeois S, Gruol D, Newby R, Rajah F . Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol. 1993; 7(7):840-51. DOI: 10.1210/mend.7.7.8105374. View